A Texas medical company is leading the fight against COVID-19. On June 25, Austin-based Babson Diagnostics said it has received an emergency use authorization from the Food & Drug Administration for its SARS-CoV-2 IgG Antibody Test.
The blood test helps identify if a person has an "adaptive immune response to SARS-CoV-2 [aka COVID-19]" by testing for antibodies. Antibodies are proteins that help fight off infections and usually provide immunity, though the Centers for Disease Control cautions that this is not yet known for COVID-19 antibodies.
“Not only is serology a crucial tool for the research and understanding of COVID-19, we believe it will become an essential component of ongoing preventive medicine,” said Eric Olson, Babson’s founder and CEO, in a release. “The early success of our assays, combined with our ongoing clinical studies and research partnerships, will provide pivotal insights into COVID-19 immunity and help us develop future generations of tests."
Babson is one of only five clinical laboratories to receive emergency use authorization from the FDA for a serology (blood) test, including the prestigious Mount Sinai Laboratory - Wadsworth Center in New York.
Since Babson launched its test on April 30, it's been offering it for free to frontline and healthcare workers. It's also working with research centers, including Dell Medical School at The University of Texas at Austin, to conduct clinical studies to help with COVID-19 research — and future pandemics.
“When COVID-19 hit the U.S. and eventually Austin, the Babson team was inspired to contribute to the fight against one of the largest threats to global health in generations,” said Chris DiPasquale, director of assay development for Babson. “While launching the aC19G1 test has been a significant achievement for Babson, it is only the first step in supporting long-term public health and national security."